doi: 10.3389/fphar.2021.632295 Received 07 December 2020 Accepted 13 April 2021 Published 10 June 2021 Volume 12 - 2021 Edited by Chiara Bianca Maria Platania, University of Catania, Italy Reviewed by Doreen Schmidl, Medical University of Vienna, Austria Francesca Lazzara, University of Catania, Italy Updates Copyright 2021 Zlatar, Kokot, Vuletic, Masnec, Kralj, Perisa, Barisic, Radic, Milanovic, Drmic, Seiwerth and Sikiric
As a triple agonist targeting GLP-1, GIP and glucagon receptors, it delivers comparable weight loss around 24% body weight reduction over 48 weeks in clinical trials while the GIP pathway actively preserves muscle
orally as a supplement
Some of the commenters referenced the Arkansas House Concurrent Resolution 1007 (HCR1007) and stated that the Arkansas General Assembly adopted HCR1007 during the 2025 Regular Session and urged CMS to reevaluate Arkansas' GPCI treatment and create distinct PFS localities for Little Rock-North Little Rock-Conway (CBSA 30780) and Fayetteville-Springdale-Rogers (CBSA 2220)
